Melinda L. Telli
- Oncology top 0.5%
- PARP inhibition in cancer therapy 35
- HER2/EGFR in Cancer Research 28
- Cancer Immunotherapy and Biomarkers 23
- Cancer Research top 1%
- Cancer Genomics and Diagnostics 23
- Breast Cancer Treatment Studies 21
-
- Advanced Breast Cancer Therapies 28
- Molecular Biology top 5%
- DNA Repair Mechanisms 25
-
- BRCA gene mutations in cancer 25
- Co-authors
- Ronald WittelesRobert W. CarlsonJames M. FordAlice E. GuardinoSharon A. HuntGeorge A. FisherS. SrinivasJoseph C. Wu
- Journals
- Journal of Clinical Oncology (35 papers)Cancer Research (18 papers)Annals of Oncology (6 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Melinda L. Telli
122 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 3.4k
- Cancer Research 1.7k
- Pulmonary and Respiratory Medicine 1.2k
- Cardiology and Cardiovascular Medicine 820
- Molecular Biology 1.8k
Countries citing papers authored by Melinda L. Telli
This map shows the geographic impact of Melinda L. Telli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melinda L. Telli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melinda L. Telli more than expected).
Fields of papers citing papers by Melinda L. Telli
This network shows the impact of papers produced by Melinda L. Telli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melinda L. Telli. The network helps show where Melinda L. Telli may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Melinda L. Telli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 18 | |
| 4 | 2024 | 7 | |
| 5 | 2024 | 3 | |
| 6 | 2023 | 67 | |
| 7 | 2023 | 21 | |
| 8 | 2020 | 76 | |
| 9 | 2019 | 148 | |
| 10 | 2019 | 23 | |
| 11 | 2018 | 67 | |
| 12 | 2018 | 88 | |
| 13 | 2018 | 55 | |
| 14 | 2018 | 20 | |
| 15 | 2018 | 141 | |
| 16 | 2017 | 55 | |
| 17 | Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicitybreakdown → | 2016 | 533 |
| 18 | 2010 | 137 | |
| 19 | 2010 | 20 | |
| 20 | 2009 | 30 |
About Melinda L. Telli
Melinda L. Telli is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 128 papers that have together received 5.4k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (35 papers), HER2/EGFR in Cancer Research (28 papers), Advanced Breast Cancer Therapies (28 papers), DNA Repair Mechanisms (25 papers), BRCA gene mutations in cancer (25 papers), Cancer Genomics and Diagnostics (23 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Breast Cancer Treatment Studies (21 papers). The work is most often cited by research in Oncology (3.4k citations), Cancer Research (1.7k citations) and Pulmonary and Respiratory Medicine (1.2k citations). Melinda L. Telli has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ronald Witteles, Robert W. Carlson, James M. Ford, Alice E. Guardino, Sharon A. Hunt, George A. Fisher, S. Srinivas, Joseph C. Wu, Shaveta Vinayak and Allison W. Kurian. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Journal of the National Comprehensive Cancer Network and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.